Rhenman & Partners Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Rhenman & Partners Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-48,000	Closed	-$1.32M	–	94
2024 Q1	$1.32M	Sell	48,000 -2,000	-4%	-$55.6K	0.13%	80
2023 Q4	$1.52M	Hold	50,000	–	–	0.15%	77
2023 Q3	$1.58M	Hold	50,000	–	–	0.17%	77
2023 Q2	$2.04M	Hold	50,000	–	–	0.21%	74
2023 Q1	$1.8M	Hold	50,000	–	–	0.2%	77
2022 Q4	$1.74M	Hold	50,000	–	–	0.18%	86
2022 Q3	$2.64M	Hold	50,000	–	–	0.28%	78
2022 Q2	$2.59M	Hold	50,000	–	–	0.29%	73
2022 Q1	$3.63M	Buy	+50,000	New	+$4.24M	0.36%	72

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rhenman & Partners Asset Management's NTLA Position: Q2 2024 in Review

Rhenman & Partners Asset Management sold out of Intellia Therapeutics (NTLA) in Q2 2024, closing a stake of 48,000 shares — an estimated $1.32M sold.

Rhenman & Partners Asset Management first reported a position in NTLA in Q1 2022 and held it in 9 quarters. The position peaked at $3.63M in Q1 2022. 290 funds tracked by Wall St. Rank hold NTLA as of Q2 2024.

Rhenman & Partners Asset Management reported no remaining Intellia Therapeutics position as of Q2 2024 after selling out during the quarter.
Rhenman & Partners Asset Management sold 48,000 Intellia Therapeutics shares in Q2 2024, an estimated $1.32M.
Rhenman & Partners Asset Management first reported a position in Intellia Therapeutics in Q1 2022 and held it in 9 quarters.
Rhenman & Partners Asset Management's Intellia Therapeutics position peaked at $3.63M in Q1 2022.
290 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2024.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.